Form 4: United Therapeutics Exec Sells Shares Via 10b5-1 Plan

United Therapeutics Corp. CFO and Treasurer James Edgemond reported the sale of 10,000 shares of common stock on May 7, 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• James Edgemond, CFO and Treasurer of United Therapeutics Corp., reported transactions on May 7, 2026.
• These transactions involved the exercise of 10,000 stock options at an exercise price of $135.42 per share.
• Following the exercise, 10,000 shares of common stock were sold.
• The sales were conducted under a Rule 10b5-1 trading plan established on October 31, 2025, which is designed to satisfy affirmative defense conditions for insider trading.
• The weighted average sale price for these shares was approximately $573.94, with individual trades occurring at prices ranging from $569.69 to $597.54.
• After these transactions, Edgemond beneficially owns 21,156 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While a significant number of shares were sold by a key executive, the execution via a pre-established Rule 10b5-1 plan mitigates concerns about insider trading and suggests a planned divestment rather than a reaction to negative non-public information.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider-trading-related sales.
• The exercise of options at $135.42 and sale at significantly higher prices ($569.69 - $597.54) suggests a profitable outcome for the executive on these specific options.

Negatives

• A significant number of shares (10,000) were sold by a key executive.
• The sale represents a disposal of equity, which could be interpreted negatively by the market if not contextualized by the 10b5-1 plan.

Risks

• Potential for negative market perception due to a large sale by a high-ranking executive, despite the Rule 10b5-1 plan.
• The weighted average sale price of $573.94 indicates a substantial value realized from the sale.

Future Outlook

This filing pertains to past transactions and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• The exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected for various sales executed at weighted average prices.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by United Therapeutics' CFO is a common practice to facilitate stock sales by executives while mitigating concerns about insider trading, especially in the biotechnology sector where stock prices can be volatile.

Stakeholder Impact

• Shareholders: May observe the sale by a key executive, but the Rule 10b5-1 plan provides a degree of reassurance against insider trading concerns.
• Employees: The sale by a senior executive does not directly impact employee stock options or benefits but may influence internal sentiment.
• Creditors/Suppliers: No direct impact is indicated by this filing.

Next Steps

• No specific next steps are outlined in this filing beyond the completion of the reported transactions.

Key Dates

Keywords

Form 4, SEC Filing, United Therapeutics, UTHR, Insider Trading, Rule 10b5-1, Stock Options, Share Sale, CFO, Treasurer, Beneficial Ownership